WonderTx
Extrapolative AI to unlock First-in-Class drugs
About WonderTx
We’re an AI-native biotech, working on replacing needles with pills. Many drugs, like insulin or Ozempic, are wonderful except you have to inject them. We discover new molecules that you can take as a pill instead. Because the pills operate on biology which has been shown to be effective in people, rather than merely in animal models of disease, we avoid what has historically been the single biggest risk in drug discovery. This should dramatically increase our probability of success. There’s $200B of treatable diseases and validated human biology without a pill because discovery programs lack a tractable chemical starting point. This is a zero-shot inference problem, because these targets have no training data, so LLMs and other historical interpolative AI approaches are insufficient. Instead, we are building our own extrapolative frontier models that reason beyond their training data. Most critically, we have repeatedly validated our platform on both our own and partner programs. On 4 biologically- and structurally-diverse targets where we had zero training data, we successfully picked binders that were validated experimentally, with confirmation ranging from primary screen hits to crystallographic structures.
Founder
Abraham Heifets
Founder
Founder and CEO of A Company in Stealth Mode. Previously, cofounded Atomwise, the first company to deploy deep learning for structure-based drug design ($220+ million in funding; 100 hires; signed $5B in total partnership value with Sanofi, Bayer, Eli Lilly, etc; ran largest AI-driven drug discovery experiment w/ 600+ researchers in 30 countries). Even more previous: PhD @ U of Toronto; inventor on 15 patents + applications; IBM Research; AI for Cornell’s world champion robotic soccer team.